1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Lidocaine hydrochloride and epinephrine injection, solution (Hospira, Inc.)

Trade Name: Not established
Synonyms: Lignoocaine with epinephrine
Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product anesthetic agent

Details of the Supplier of the Safety Data Sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Hospira UK Limited
Horizon
Honey Lane
Hurley
Maidenhead, SL6 6RJ
United Kingdom

Emergency telephone number:
Chemtrec (24 hours): 1-800-424-9300
International Chemtrec (24 hours): +1-703-527-3887

Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

Label Elements

Signal Word: Not Classified
Hazard Statements: Not classified in accordance with international standards for workplace safety.

Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous
SAFETY DATA SHEET

Material Name: Lidocaine hydrochloride and epinephrine injection, solution (Hospira, Inc.)
Revision date: 27-Jul-2017

3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epinephrine</td>
<td>51-43-4</td>
<td>200-098-7</td>
<td>Acute Tox. 2 (H300)</td>
<td>&lt;= 0.002</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Acute Tox. 2 (H310)</td>
<td></td>
</tr>
<tr>
<td>HYDROCHLORIC ACID</td>
<td>7647-01-0</td>
<td>231-595-7</td>
<td>Skin Corr.1B (H314)</td>
<td>**</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>STOT SE 3 (H335)</td>
<td></td>
</tr>
<tr>
<td>Lidocaine Hydrochloride</td>
<td>73-78-9</td>
<td>200-803-8</td>
<td>Acute Tox.4 (H302)</td>
<td>&lt;= 2</td>
</tr>
<tr>
<td>SODIUM HYDROXIDE</td>
<td>1310-73-2</td>
<td>215-185-5</td>
<td>Skin Corr. 1A (H314)</td>
<td>**</td>
</tr>
<tr>
<td>Sodium chloride</td>
<td>7647-14-5</td>
<td>231-598-3</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Sodium metabisulfite USP</td>
<td>7681-57-4</td>
<td>231-673-0</td>
<td>Acute Tox. 4 (H302)</td>
<td>&lt;0.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Eye Dam. 1 (H318)</td>
<td></td>
</tr>
<tr>
<td>Water for injection</td>
<td>7732-18-5</td>
<td>231-791-2</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

**Eye Contact:**
Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

**Skin Contact:**
Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

**Ingestion:**
Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:**
Remove to fresh air and keep patient at rest. Seek medical attention immediately.

**Most Important Symptoms and Effects, Both Acute and Delayed**

**Symptoms and Effects of Exposure:**
For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

**Medical Conditions Aggravated by Exposure:**
None known

**Indication of the Immediate Medical Attention and Special Treatment Needed**

**Notes to Physician:**
None

5. FIRE FIGHTING MEASURES

**Extinguishing Media:**
Extinguish fires with CO2, extinguishing powder, foam, or water.

**Special Hazards Arising from the Substance or Mixture**

PZ03472
Hazardous Combustion Products:
Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards:
Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters
During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting:
Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Additional Consideration for Large Spills:
Contain the source of the spill or leak if it is safe to do so. Collect spill with a non-combustible absorbent material and transfer to labeled container for disposal.

7. HANDLING AND STORAGE

Precautions for Safe Handling
Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls. Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8).

Conditions for Safe Storage, Including any Incompatibilities
Storage Conditions: Store as directed by product packaging.
Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters
Refer to available public information for specific member state Occupational Exposure Limits.

HYDROCHLORIC ACID

ACGIH Ceiling Threshold Limit: 2 ppm
Australia PEAK 5 ppm
7.5 mg/m³
Austria OEL - MAKs 5 ppm
8 mg/m³
Belgium OEL - TWA 5 ppm
8 mg/m³
Bulgaria OEL - TWA 5 ppm
8.0 mg/m³
Cyprus OEL - TWA 5 ppm
8 mg/m³
Czech Republic OEL - TWA 8 mg/m³
## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

<table>
<thead>
<tr>
<th>Country</th>
<th>Exposure Standard</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estonia OEL - TWA</td>
<td>5 ppm, 8 mg/m³</td>
</tr>
<tr>
<td>Germany - TRGS 900 - TWA</td>
<td>2 ppm, 3 mg/m³</td>
</tr>
<tr>
<td>Germany (DFG) - MAK</td>
<td>2 ppm, 3.0 mg/m³</td>
</tr>
<tr>
<td>Greece OEL - TWA</td>
<td>5 ppm, 7 mg/m³</td>
</tr>
<tr>
<td>Hungary OEL - TWA</td>
<td>8 mg/m³</td>
</tr>
<tr>
<td>Ireland OEL - TWA</td>
<td>5 ppm, 8 mg/m³</td>
</tr>
<tr>
<td>Italy OEL - TWA</td>
<td>5 ppm, 8 mg/m³</td>
</tr>
<tr>
<td>Japan - OELs - Ceilings</td>
<td>2 ppm, 3.0 mg/m³</td>
</tr>
<tr>
<td>Latvia OEL - TWA</td>
<td>5 ppm, 8 mg/m³</td>
</tr>
<tr>
<td>Lithuania OEL - TWA</td>
<td>5 ppm, 8 mg/m³</td>
</tr>
<tr>
<td>Luxembourg OEL - TWA</td>
<td>5 ppm, 8 mg/m³</td>
</tr>
<tr>
<td>Malta OEL - TWA</td>
<td>5 ppm, 8 mg/m³</td>
</tr>
<tr>
<td>Netherlands OEL - TWA</td>
<td>8 mg/m³</td>
</tr>
<tr>
<td>Poland OEL - TWA</td>
<td>5 ppm, 8 mg/m³</td>
</tr>
<tr>
<td>Portugal OEL - TWA</td>
<td>5 ppm, 8 mg/m³</td>
</tr>
<tr>
<td>Romania OEL - TWA</td>
<td>5 ppm, 8 mg/m³</td>
</tr>
<tr>
<td>Slovakia OEL - TWA</td>
<td>5 ppm, 8 mg/m³</td>
</tr>
<tr>
<td>Slovenia OEL - TWA</td>
<td>5 ppm, 8.0 mg/m³</td>
</tr>
<tr>
<td>Spain OEL - TWA</td>
<td>5 ppm, 7.6 mg/m³</td>
</tr>
<tr>
<td>Switzerland OEL - TWA</td>
<td>2 ppm, 3.0 mg/m³</td>
</tr>
<tr>
<td>Vietnam OEL - TWA</td>
<td>5 ppm, 3.0 mg/m³</td>
</tr>
</tbody>
</table>

### SODIUM HYDROXIDE

<table>
<thead>
<tr>
<th>Country</th>
<th>Exposure Standard</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACGIH Ceiling Threshold Limit:</td>
<td>2 mg/m³</td>
</tr>
<tr>
<td>Australia PEAK</td>
<td>2 mg/m³</td>
</tr>
<tr>
<td>Austria OEL - MAKs</td>
<td>2 mg/m³</td>
</tr>
<tr>
<td>Bulgaria OEL - TWA</td>
<td>2.0 mg/m³</td>
</tr>
<tr>
<td>Czech Republic OEL - TWA</td>
<td>1 mg/m³</td>
</tr>
<tr>
<td>Estonia OEL - TWA</td>
<td>1 mg/m³</td>
</tr>
<tr>
<td>France OEL - TWA</td>
<td>2 mg/m³</td>
</tr>
<tr>
<td>Greece OEL - TWA</td>
<td>2 mg/m³</td>
</tr>
<tr>
<td>Hungary OEL - TWA</td>
<td>2 mg/m³</td>
</tr>
<tr>
<td>Japan - OELs - Ceilings</td>
<td>2 mg/m³</td>
</tr>
<tr>
<td>Latvia OEL - TWA</td>
<td>0.5 mg/m³</td>
</tr>
<tr>
<td>OSHA - Final PELS - TWA</td>
<td>2 mg/m³</td>
</tr>
</tbody>
</table>

Material Name: Lidocaine hydrochloride and epinephrine injection, solution (Hospira, Inc.)

Revision date: 27-Jul-2017

Version: 1.0
Exposure Controls

Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section. Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Personal Protective Equipment:

Hands:
Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

Eyes:
Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin:
Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

Pfizer Occupational Exposure Band (OEB):

Epinephrine
OEB 4 - Skin (control exposure to the range of 1ug/m³ to <10ug/m³, provide additional precautions to protect from skin contact)

Lidocaine Hydrochloride
OEB 2 (control exposure to the range of 100ug/m³ to < 1000ug/m³)

Sodium chloride
OEB 1 (control exposure to the range of 1000ug/m³ to 3000ug/m³)

Sodium chloride

<table>
<thead>
<tr>
<th>Country</th>
<th>OEL - TWA</th>
<th>OEL - TWAs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poland</td>
<td>0.5 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Slovakia</td>
<td>2 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Slovenia</td>
<td>2 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Sweden</td>
<td>1 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Switzerland</td>
<td>2 mg/m³</td>
<td></td>
</tr>
</tbody>
</table>

Sodium metabisulfite USP

<table>
<thead>
<tr>
<th>Country</th>
<th>OEL - TWA</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACGIH</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Australia</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Belgium</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Denmark</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>France</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Greece</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Ireland</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Portugal</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Spain</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Switzerland</td>
<td>5 mg/m³</td>
</tr>
</tbody>
</table>

Epinephrine

<table>
<thead>
<tr>
<th>Country</th>
<th>OEL - TWA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Greece</td>
<td>0.5 mg/m³</td>
</tr>
<tr>
<td>Ireland</td>
<td>0.5 mg/m³</td>
</tr>
<tr>
<td>Latvia</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Lithuania</td>
<td>5 mg/m³</td>
</tr>
</tbody>
</table>

Material Name: Lidocaine hydrochloride and epinephrine injection, solution (Hospira, Inc.)

Revision date: 27-Jul-2017

PZ03472
SAFETY DATA SHEET

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Respiratory protection: Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical State</td>
<td>Solution</td>
</tr>
<tr>
<td>Odor</td>
<td>No data available.</td>
</tr>
<tr>
<td>Molecular Formula</td>
<td>Mixture</td>
</tr>
<tr>
<td>Solvent Solubility</td>
<td>No data available.</td>
</tr>
<tr>
<td>Water Solubility</td>
<td>No data available.</td>
</tr>
<tr>
<td>pH</td>
<td>No data available.</td>
</tr>
<tr>
<td>Melting/Freezing Point (°C)</td>
<td>No data available.</td>
</tr>
<tr>
<td>Boiling Point (°C)</td>
<td>No data available.</td>
</tr>
<tr>
<td>Partition Coefficient: (Method, pH, Endpoint, Value)</td>
<td>No data available.</td>
</tr>
<tr>
<td>Water for injection</td>
<td>No data available.</td>
</tr>
<tr>
<td>Sodium chloride</td>
<td>No data available.</td>
</tr>
<tr>
<td>Sodium metabisulfite USP</td>
<td>No data available.</td>
</tr>
<tr>
<td>SODIUM HYDROXIDE</td>
<td>No data available.</td>
</tr>
<tr>
<td>HYDROCHLORIC ACID</td>
<td>No data available.</td>
</tr>
<tr>
<td>Epinephrine</td>
<td>No data available.</td>
</tr>
<tr>
<td>Lidocaine Hydrochloride</td>
<td>No data available.</td>
</tr>
<tr>
<td>Decomposition Temperature (°C)</td>
<td>No data available.</td>
</tr>
<tr>
<td>Evaporation Rate (Gram/s)</td>
<td>No data available.</td>
</tr>
<tr>
<td>Vapor Pressure (kPa)</td>
<td>No data available.</td>
</tr>
<tr>
<td>Vapor Density (g/ml)</td>
<td>No data available.</td>
</tr>
<tr>
<td>Relative Density</td>
<td>No data available.</td>
</tr>
<tr>
<td>Viscosity</td>
<td>No data available.</td>
</tr>
<tr>
<td>Flammability</td>
<td></td>
</tr>
<tr>
<td>Autoignition Temperature (Solid) (°C):</td>
<td>No data available.</td>
</tr>
<tr>
<td>Flammability (Solids):</td>
<td>No data available.</td>
</tr>
<tr>
<td>Flash Point (Liquid) (°C):</td>
<td>No data available.</td>
</tr>
<tr>
<td>Upper Explosive Limits (Liquid) (% by Vol.):</td>
<td>No data available.</td>
</tr>
<tr>
<td>Lower Explosive Limits (Liquid) (% by Vol.):</td>
<td>No data available.</td>
</tr>
</tbody>
</table>

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions

PZ03472
10. STABILITY AND REACTIVITY

Oxidizing Properties: No data available
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects
General Information: There are no data for this formulation. The information included in this section describes the potential hazards of the individual ingredients.

Short Term:
Harmful if swallowed May cause mild eye irritation. May cause slight skin irritation. (based on components) Drugs of this class have been associated with rare, but potentially serious cardiac events. These events have not been observed from occupational exposures, however, those with preexisting cardiovascular illnesses may be at increased risk from exposure.

Known Clinical Effects:
Adverse effects associated with therapeutic use include dizziness, nervousness, agitation, drowsiness, apprehension, euphoria, blurred/double vision, slurred speech, tremors, convulsions, and seizure. Respiratory depression and arrest may follow. Other, more serious effects seen with IV use of this drug, particularly when it is administered rapidly, are cardiovascular collapse, central nervous system depression, and/or hypotension.

Acute Toxicity: (Species, Route, End Point, Dose)

Sodium chloride
- Rat Oral LD50 3000 mg/kg
- Mouse Oral LD50 4000 mg/kg

HYDROCHLORIC ACID
- Rat Oral LD50 238-277 mg/kg

Epinephrine
- Rat Dermal LD50 62 mg/kg
- Rat Oral LD50 30mg/kg

Lidocaine Hydrochloride
- Rat Oral LD50 317 mg/kg
- Rat Para-periosteal LD50 25mg/kg
- Rat Intraperitoneal LD50 133mg/kg
- Mouse Oral LD50 292mg/kg
- Mouse Intravenous LD50 19.5mg/kg

Irritation / Sensitization: (Study Type, Species, Severity)

Sodium chloride
- Eye Irritation Rabbit Moderate
- Skin Irritation Rabbit Mild

Lidocaine Hydrochloride
- Eye Irritation Rabbit Mild
- Skin Irritation Rabbit Mild
11. TOXICOLOGICAL INFORMATION

HYDROCHLORIC ACID
30 Day(s)

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

HYDROCHLORIC ACID
Fertility and Embryonic Development

Epinephrine
Embryo / Fetal Development  Rat  Intravenous  Dose not specified  Not teratogenic
Embryo / Fetal Development  Rabbit  Subcutaneous  30 times human dose  NOAEL  Developmental toxicity
Embryo / Fetal Development  Mouse  Subcutaneous  7 times human dose  NOAEL  Developmental toxicity

Lidocaine Hydrochloride
Embryo / Fetal Development  Rat  Subcutaneous  30 mg/kg  NOAEL  Not teratogenic
Embryo / Fetal Development  Rat  Intraperitoneal  56 mg/kg  NOAEL  Not Teratogenic
Embryo / Fetal Development  Rat  Intraperitoneal  72 mg/kg/day  NOAEL  Not Teratogenic
Embryo / Fetal Development  Rat  Intravenous  500 mg/kg/day  LOAEL  Fetotoxicity
Embryo / Fetal Development  Rat  Intraperitoneal  6 mg/kg  LOAEL  Developmental toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

HYDROCHLORIC ACID
Bacterial Mutagenicity (Ames)  Salmonella  Negative

In Vivo Micronucleus  Rat  Negative

Epinephrine
Bacterial Mutagenicity (Ames)  Salmonella  Negative
Sister Chromatid Exchange  Negative with activation
Sister Chromatid Exchange  Chinese Hamster Ovary (CHO) cells  Equivocal without activation

Lidocaine Hydrochloride
Bacterial Mutagenicity (Ames)  Salmonella, E. coli  Negative

In Vitro Chromosome Aberration  Human Lymphocytes  Negative
In Vivo Micronucleus  Mouse  Negative

Carcinogen Status:
None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

Sodium metabisulfite USP
IARC:  Group 3 (Not Classifiable)

HYDROCHLORIC ACID
IARC:  Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview:
Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.
SAFETY DATA SHEET

Material Name: Lidocaine hydrochloride and epinephrine injection, solution (Hospira, Inc.)
Revision date: 27-Jul-2017

Toxicity: No data available
Persistence and Degradability: No data available
Bio-accumulative Potential: No data available
Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Epinephrine
RCRA - P Series Wastes Listed

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Epinephrine
- CERCLA/SARA 313 Emission reporting Not Listed
- CERCLA/SARA Hazardous Substances and their Reportable Quantities: 1000 lb 454 kg
- California Proposition 65 Not Listed
- Inventory - United States TSCA - Sect. 8(b) Present
- Australia (AICS): Present
- Standard for the Uniform Scheduling for Drugs and Poisons: Schedule 3 Schedule 4

PZ03472
15. REGULATORY INFORMATION

EU EINECS/ELINCS List 200-098-7

HYDROCHLORIC ACID
CERCLA/SARA 313 Emission reporting 1.0 %
CERCLA/SARA Hazardous Substances 5000 lb
and their Reportable Quantities:
2270 kg
CERCLA/SARA - Section 302 Extremely Hazardous
500 lb
TPQs
CERCLA/SARA - Section 302 Extremely Hazardous
Substances EPCRA RQs
California Proposition 65 Not Listed
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
Standard for the Uniform Scheduling Schedule 5
for Drugs and Poisons:
EU EINECS/ELINCS List 231-595-7

Lidocaine Hydrochloride
CERCLA/SARA 313 Emission reporting Not Listed
California Proposition 65 Not Listed
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
EU EINECS/ELINCS List 200-803-8

SODIUM HYDROXIDE
CERCLA/SARA 313 Emission reporting Not Listed
CERCLA/SARA Hazardous Substances 1000 lb
and their Reportable Quantities:
454 kg
California Proposition 65 Not Listed
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
Standard for the Uniform Scheduling Schedule 5
for Drugs and Poisons:
EU EINECS/ELINCS List 215-185-5

Sodium chloride
CERCLA/SARA 313 Emission reporting Not Listed
California Proposition 65 Not Listed
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
EU EINECS/ELINCS List 231-598-3

Sodium metabisulfite USP
CERCLA/SARA 313 Emission reporting Not Listed
California Proposition 65 Not Listed
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
Standard for the Uniform Scheduling Schedule 5
for Drugs and Poisons:
EU EINECS/ELINCS List 231-673-0

Water for injection
15. REGULATORY INFORMATION

CERCLA/SARA 313 Emission reporting: Not Listed
California Proposition 65: Not Listed
Inventory - United States TSCA - Sect. 8(b): Present
Australia (AICS): Present
REACH - Annex IV - Exemptions from the obligations of Register: Present
EU EINECS/ELINCS List: 231-791-2

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3
Acute toxicity, oral-Cat.3; H302 - Harmful if swallowed
Serious eye damage/eye irritation-Cat.1; H318 - Causes serious eye damage
Skin corrosion/irritation-Cat.1A; Skin corrosion/irritation-Cat.1B; H314 - Causes severe skin burns and eye damage
Acute toxicity, dermal-Cat.2; H310 - Fatal in contact with skin
Specific target organ toxicity, single exposure; Respiratory tract irritation-Cat.3; H335 - May cause respiratory irritation
Acute toxicity, oral-Cat.2; H300 - Fatal if swallowed

Data Sources: Publicly available toxicity information. Pfizer proprietary drug development information. Safety data sheets for individual ingredients.

Reasons for Revision: New data sheet.

Revision date: 27-Jul-2017

Prepared by: Product Stewardship Hazard Communication

Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet